Snow Capital Management’s Myriad Genetics MYGN Stock Holding History

Snow Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-827,803	Closed	-$28.2M	–	142
2014 Q4	$28.2M	Sell	827,803 -227,211	-22%	-$8.06M	0.85%	34
2014 Q3	$40.7M	Sell	1,055,014 -36,213	-3%	-$1.35M	1.41%	31
2014 Q2	$42.5M	Sell	1,091,227 -726,174	-40%	-$27M	1.47%	30
2014 Q1	$62.1M	Buy	1,817,401 +278,716	+18%	+$8.64M	2.44%	19
2013 Q4	$32.3M	Buy	1,538,685 +1,524,810	+10,990%	+$38.6M	1.31%	32
2013 Q3	$326K	Buy	+13,875	New	+$394K	0.01%	108

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Snow Capital Management's MYGN Position: Q1 2015 in Review

Snow Capital Management sold out of Myriad Genetics (MYGN) in Q1 2015, closing a stake of 827,803 shares — an estimated $28.2M sold.

Snow Capital Management first reported a position in MYGN in Q3 2013 and held it in 6 quarters. The position peaked at $62.1M in Q1 2014. 252 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

Snow Capital Management reported no remaining Myriad Genetics position as of Q1 2015 after selling out during the quarter.
Snow Capital Management sold 827,803 Myriad Genetics shares in Q1 2015, an estimated $28.2M.
Snow Capital Management first reported a position in Myriad Genetics in Q3 2013 and held it in 6 quarters.
Snow Capital Management's Myriad Genetics position peaked at $62.1M in Q1 2014.
252 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on Snow Capital Management's 13F filing for Q1 2015, filed 12 May 2015.